SCHEMBL5113870

SCHEMBL5113870

CCOCC(=N)C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
NPSR1 Q6W5P4 1/20 0.39
GLO1 Q04760 1/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
THRB P10828 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
MAPT P10636 1/20 0.35
TRPA1 O75762 1/20 0.34
CYP2D6 P10635 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5108504 0.98 ALDH1A1 (0.39) ALDH1A1NPSR1GLO1HSD17B10LMNA
SCHEMBL18526612 0.90 ALDH1A1 (0.36) ALDH1A1NPSR1GLO1HSD17B10LMNA
SCHEMBL20156037 0.83 NPSR1 (0.43) ALDH1A1NPSR1GLO1HSD17B10LMNA
SCHEMBL19322774 0.82 ALDH1A1 (0.40) ALDH1A1NPSR1GLO1HSD17B10LMNA
SCHEMBL13351478 0.80 ALDH1A1 (0.39) ALDH1A1NPSR1GLO1HSD17B10LMNA
SCHEMBL4364932 0.78
SCHEMBL23542529 0.76
SCHEMBL9622001 0.76
SCHEMBL5431411 0.76 ALDH1A1 (0.45) ALDH1A1NPSR1GLO1HSD17B10LMNA
SCHEMBL10263392 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7335774-B2 Quinolinone derivatives NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-02-26 US claimed
US-20050209456-A1 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents CHIRON CORPORATION 2005-09-22 US claimed
US-20230151074-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209456-A1 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents KDR, FLT4, FLT1 ALDH1A1 1081/4885NPSR1 4226/4885GLO1 4152/4885
US-20230151074-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR ALDH1A1 3938/4885NPSR1 150/4885GLO1 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.